Sector News

Pfizer, Amgen will rake in billions during ‘golden age’ for biosimilars: Analyst

August 6, 2020
Life sciences

During Pfizer’s second-quarter earnings conference call last week, many analysts were so focused on the company’s potential future payoff from its COVID-19 vaccine effort that they may have overlooked one area of the business that’s paying off now: biosimilars.

Pfizer’s global biosim sales grew 36% during the quarter to $289 million, driven largely by cancer drugs. The significance of that growth wasn’t lost on Bernstein analyst Ronny Gal. In a note to investors earlier this week, he singled out Pfizer, along with Amgen, as proof that the U.S. biosimilars industry has entered a “golden age.”

In February, Pfizer became the first company to have three monoclonal antibody biosimilars on the market in the U.S., all of which are discounted versions of Roche cancer drugs: Zirabev (Avastin), Ruxience (Rituxan) and Trazimera (Herceptin). During the conference call, Pfizer CEO Albert Bourla cited strong “early results” from all three launches, particularly Trazimera, which saw high demand overseas, he said.

But investors shouldn’t discount the potential of the U.S. biosimilars market, Gal said. To prove the point, Gal crunched the numbers on Pfizer’s biosimilar version of Remicade, Inflectra, which only has a 10% share of the U.S. market. Pfizer claims 30% of the European market for biosimilar Remicade—but it’s able to charge much more in the U.S. So sales of the product in the U.S. were $158 million, versus just $116 million in Europe in the second quarter.

“Thus, the US ‘failed market’ is much better commercially than price-sensitive EU,” Gal wrote.

All in all, Pfizer’s biosimilar sales are running at an annualized rate of $2.1 billion, and the company is set to eventually bring in close to $3 billion a year in biosimilar revenues, Gal predicted.

Amgen’s biosimilar business pulled in $357 million in the second quarter and is annualizing at $1.4 billion, Gal estimated. The company dominates some markets in the U.S., including those for biosimilar Herceptin, where its Kanjinti holds 32% share, and Avastin, for which it claims 39% share with Mvasi.

“Here the addition of [biosimilar] Remicade and later this year the launch of Rituxan should push the business toward $2 billion,” Gal wrote.

During Amgen’s second-quarter conference call, executives were asked to predict whether future competition in the markets for biosimilar Herceptin and Avastin might threaten the company’s market share.

Murdo Gordon, the company’s head of global commercial operations, said he’s not worried, at least not in the short term, even though COVID-19 shutdowns did delay some dosing of injectable cancer drugs.

“I think providers are looking for a lot of places where they can extract more value in the healthcare system. So we’ve been pleased with the uptake,” Gordon said. “I would say we’re less challenged on share but you may see some net price effects of multiple competitors entering.”

Bernstein’s Gal also acknowledged that pricing pressure could end the golden age for biosimilars—but not anytime soon. “There will be a transition [to a] commodity model, but perhaps not before mid-decade as the system does see gradual discounts,” Gal wrote.

By: Arlene Weintraub

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach